Copyright Reports & Markets. All rights reserved.

Global Biosimilars Insulin Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Biosimilars Insulin Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Biosimilars Insulin Market Size Growth Rate by Product
      • 1.4.2 Insulin Glargine Basaglar
      • 1.4.3 Insulin Lantus
    • 1.5 Market by End User
      • 1.5.1 Global Biosimilars Insulin Market Size Growth Rate by End User
      • 1.5.2 Type I Diabetes
      • 1.5.3 Type II Diabetes
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Biosimilars Insulin Market Size
      • 2.1.1 Global Biosimilars Insulin Revenue 2014-2025
      • 2.1.2 Global Biosimilars Insulin Sales 2014-2025
    • 2.2 Biosimilars Insulin Growth Rate by Regions
      • 2.2.1 Global Biosimilars Insulin Sales by Regions
      • 2.2.2 Global Biosimilars Insulin Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Biosimilars Insulin Sales by Manufacturers
      • 3.1.1 Biosimilars Insulin Sales by Manufacturers
      • 3.1.2 Biosimilars Insulin Sales Market Share by Manufacturers
      • 3.1.3 Global Biosimilars Insulin Market Concentration Ratio (CR5 and HHI)
    • 3.2 Biosimilars Insulin Revenue by Manufacturers
      • 3.2.1 Biosimilars Insulin Revenue by Manufacturers (2014-2019)
      • 3.2.2 Biosimilars Insulin Revenue Share by Manufacturers (2014-2019)
    • 3.3 Biosimilars Insulin Price by Manufacturers
    • 3.4 Biosimilars Insulin Manufacturing Base Distribution, Product Types
      • 3.4.1 Biosimilars Insulin Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Biosimilars Insulin Product Type
      • 3.4.3 Date of International Manufacturers Enter into Biosimilars Insulin Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Biosimilars Insulin Sales by Product
    • 4.2 Global Biosimilars Insulin Revenue by Product
    • 4.3 Biosimilars Insulin Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Biosimilars Insulin Breakdown Data by End User

    6 North America

    • 6.1 North America Biosimilars Insulin by Countries
      • 6.1.1 North America Biosimilars Insulin Sales by Countries
      • 6.1.2 North America Biosimilars Insulin Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Biosimilars Insulin by Product
    • 6.3 North America Biosimilars Insulin by End User

    7 Europe

    • 7.1 Europe Biosimilars Insulin by Countries
      • 7.1.1 Europe Biosimilars Insulin Sales by Countries
      • 7.1.2 Europe Biosimilars Insulin Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Biosimilars Insulin by Product
    • 7.3 Europe Biosimilars Insulin by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Biosimilars Insulin by Countries
      • 8.1.1 Asia Pacific Biosimilars Insulin Sales by Countries
      • 8.1.2 Asia Pacific Biosimilars Insulin Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Biosimilars Insulin by Product
    • 8.3 Asia Pacific Biosimilars Insulin by End User

    9 Central & South America

    • 9.1 Central & South America Biosimilars Insulin by Countries
      • 9.1.1 Central & South America Biosimilars Insulin Sales by Countries
      • 9.1.2 Central & South America Biosimilars Insulin Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Biosimilars Insulin by Product
    • 9.3 Central & South America Biosimilars Insulin by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Biosimilars Insulin by Countries
      • 10.1.1 Middle East and Africa Biosimilars Insulin Sales by Countries
      • 10.1.2 Middle East and Africa Biosimilars Insulin Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Biosimilars Insulin by Product
    • 10.3 Middle East and Africa Biosimilars Insulin by End User

    11 Company Profiles

    • 11.1 Eli Lilly
      • 11.1.1 Eli Lilly Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Eli Lilly Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Eli Lilly Biosimilars Insulin Products Offered
      • 11.1.5 Eli Lilly Recent Development
    • 11.2 Boehringer Ingelheim
      • 11.2.1 Boehringer Ingelheim Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Boehringer Ingelheim Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Boehringer Ingelheim Biosimilars Insulin Products Offered
      • 11.2.5 Boehringer Ingelheim Recent Development
    • 11.3 Merck
      • 11.3.1 Merck Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck Biosimilars Insulin Products Offered
      • 11.3.5 Merck Recent Development
    • 11.4 Pfizer
      • 11.4.1 Pfizer Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Pfizer Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Pfizer Biosimilars Insulin Products Offered
      • 11.4.5 Pfizer Recent Development
    • 11.5 Biocon
      • 11.5.1 Biocon Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Biocon Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Biocon Biosimilars Insulin Products Offered
      • 11.5.5 Biocon Recent Development
    • 11.6 Mylan
      • 11.6.1 Mylan Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Mylan Biosimilars Insulin Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Mylan Biosimilars Insulin Products Offered
      • 11.6.5 Mylan Recent Development

    12 Future Forecast

    • 12.1 Biosimilars Insulin Market Forecast by Regions
      • 12.1.1 Global Biosimilars Insulin Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Biosimilars Insulin Revenue Forecast by Regions 2019-2025
    • 12.2 Biosimilars Insulin Market Forecast by Product
      • 12.2.1 Global Biosimilars Insulin Sales Forecast by Product 2019-2025
      • 12.2.2 Global Biosimilars Insulin Revenue Forecast by Product 2019-2025
    • 12.3 Biosimilars Insulin Market Forecast by End User
    • 12.4 North America Biosimilars Insulin Forecast
    • 12.5 Europe Biosimilars Insulin Forecast
    • 12.6 Asia Pacific Biosimilars Insulin Forecast
    • 12.7 Central & South America Biosimilars Insulin Forecast
    • 12.8 Middle East and Africa Biosimilars Insulin Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Biosimilars Insulin Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
      Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
      The global Biosimilars Insulin market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biosimilars Insulin market based on company, product type, end user and key regions.

      This report studies the global market size of Biosimilars Insulin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilars Insulin in these regions.
      This research report categorizes the global Biosimilars Insulin market by top players/brands, region, type and end user. This report also studies the global Biosimilars Insulin market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Eli Lilly
      Boehringer Ingelheim
      Merck
      Pfizer
      Biocon
      Mylan

      Market size by Product
      Insulin Glargine Basaglar
      Insulin Lantus
      Market size by End User
      Type I Diabetes
      Type II Diabetes

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Biosimilars Insulin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Biosimilars Insulin market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Biosimilars Insulin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Biosimilars Insulin submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Biosimilars Insulin are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilars Insulin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now